La Vanguardia reports on a recent study published by Marco Milán’s lab in the journal Developmental Cell. On the basis of their findings in the fruit fly (Drosophila melanogaster), the scientists have concluded that the chromosomal instability characteristic of tumours can promote invasive behaviour in cancer.
Link to La Vanguardia: Demuestran que la inestabilidad cromosómica de tumores promueve la metástasis (in Spanish)
The digital newspaper Público and other media have echoed a study headed by the Universitat Autònoma de Barcelona (UAB) and involving researchers from the Chemistry and Molecular Pharmacology Programme at IRB Barcelona that offers a promising advance towards a treatment for Parkinson’s disease,.
Published in the journal PNAS, the study has revealed that a small molecule, called SynuClean-D, disrupts the formation of amyloid fibers of alpha-synuclein—the process that triggers the development of Parkinson’s disease—and reverses the neurodegeneration that ensues.
Jesús Garcia, Salvador Guardiola, Ernest Giralt and Xavier Salvatella are among...
El Punt Avui and La Vanguardia have published an article about the European Research Council (ERC) Proof of Concept grants. Five of them were given to centres belonging to the Barcelona Institute of Science and Technology (BIST), two corresponding to researchers Eduard Batlle and Angel R. Nebreda at IRB Barcelona.
Link to La Vanguardia: España, líder en la última convocatoria de ciencia europea (in Spanish)
Link to El Punt Avui:...
Published in Science Advances, the study shows that the TLK1 and TLK2 enzymes are critical for ensuring the copying of DNA.
Loss of TLK1 and TLK2 results in extensive DNA damage during DNA replication and in cancer cell death.
Depletion of TLK1/2 enhances the effectiveness of some chemotherapeutic agents currently being tested in clinical trials
A new computational model has allowed researchers to identify new therapeutic targets that can attack cancer cells by lowering their intracellular pH.
The study, which is the result of collaboration between IRB Barcelona, the Moffitt Cancer Center, and the University of Maryland, has been published in Nature Communications.
A team headed by Manuel Serrano at IRB Barcelona has designed a drug encapsulation system that selectively targets senescent cells.
The study paves the way for therapeutic approaches to eliminate senescent cells in many diseases, such as pulmonary fibrosis and cancer.
We all have in mind wonderful speakers, from Steve Jobs to Martin Luther King. The power of a good pitch to make a difference, to mobilise people or resources, is beyond question. For researchers, a good presentation may be the difference between being invited to be member of a consortium or not, between getting funding or not, between receiving an ERC grant or watching the grant go to someone else. On May 14-15, a group of 9 IRB Barcelona researchers (from PhD students to postdocs) participated in a 2-day course to learn about “Pitch Strategies That Get Investors to “YES”!”, organized by the Innovation Department with the support of La Caixa Foundation Young Biomedtec programme. The...
A study on breast cancer conducted at IRB Barcelona identifies the key role of p38 in safeguarding tumour cells against the excessive accumulation of DNA damage, which would otherwise cause cell death.
p38 blockage has been shown to increase the death of tumour cells, thus causing tumours to shrink.
The combination of p38 inhibitors with chemotherapeutic drugs (taxanes) strengthens, accelerates or prolongs the antitumour effect in patient-derived tumours grown in mice.
The study, published in The Journal of Cell Biology, focuses on the development of the sperm tail, the structure that enables sperm cells to swim and is therefore critical for male fertility.
IRB Barcelona scientist, Modesto Orozco has been granted 150,000 euros to optimise and validate a promising anti-tumour therapeutic tool over 18 months.